Form 4: Twist Bioscience CFO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Twist Bioscience's Chief Financial Officer, Adam Laponis, sold 3,000 shares of common stock for $40 per share under a pre-arranged 10b5-1 trading plan.
Summary
- Adam Laponis, Chief Financial Officer of Twist Bioscience Corp (TWST), reported the sale of 3,000 shares of common stock.
- The transaction occurred on January 13, 2026, with each share sold at a price of $40.
- The total value of the shares sold amounts to $120,000.
- Following this transaction, Adam Laponis beneficially owns 137,031 shares of Twist Bioscience common stock.
- The sale was executed pursuant to a Rule 10b5-1 trading plan, which was previously adopted by Mr. Laponis on May 8, 2025.
Sentiment
Score: 5
Explanation: The sentiment is neutral. While it's an insider sale, the fact that it's under a pre-arranged 10b5-1 plan mitigates any negative interpretation, as it's a scheduled liquidity event rather than a reactive sale based on new information.
Positives
- The transaction provides liquidity to the reporting person, Adam Laponis.
- The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and scheduled transaction rather than an immediate reaction to new information.
Negatives
- Insider selling, even under a 10b5-1 plan, can sometimes be perceived by the market as a lack of confidence, although this is mitigated by the pre-planned nature.
Industry Context
This transaction is a routine insider filing for a biotechnology company. Insider trading plans (10b5-1) are common among executives in the industry to manage personal finances while complying with insider trading regulations, especially given the often volatile nature of biotech stock prices.
Stakeholder Impact
- Shareholders: May view the insider sale with slight caution, though the 10b5-1 plan reduces concerns about immediate negative implications for the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 05/08/2025 | Date the Rule 10b5-1 trading plan was adopted by Adam Laponis. |
| 01/13/2026 | Date of the reported transaction (sale of common stock). |
| 01/15/2026 | Date the Form 4 was signed and filed. |
Keywords
Twist Bioscience, TWST, Adam Laponis, CFO, Insider Sale, Form 4, 10b5-1 Plan, Biotechnology, Synthetic Biology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.